Omada Health (NASDAQ:OMDA) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Omada Health (NASDAQ:OMDA - Free Report) in a report published on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $19.00 price objective on the stock.

Other analysts have also recently issued research reports about the company. Canaccord Genuity Group assumed coverage on Omada Health in a research report on Tuesday. They issued a "buy" rating and a $27.00 price target for the company. Wall Street Zen raised shares of Omada Health to a "hold" rating in a report on Monday, June 16th. The Goldman Sachs Group initiated coverage on shares of Omada Health in a research note on Tuesday. They set a "buy" rating and a $29.00 target price on the stock. Needham & Company LLC began coverage on shares of Omada Health in a report on Tuesday. They set a "buy" rating and a $23.00 price target on the stock. Finally, Barclays assumed coverage on shares of Omada Health in a research note on Tuesday. They issued an "overweight" rating and a $21.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Omada Health presently has an average rating of "Moderate Buy" and a consensus target price of $23.57.

Omada Health Stock Performance

Shares of NASDAQ:OMDA traded up $0.18 during midday trading on Tuesday, hitting $18.43. The company had a trading volume of 180,446 shares, compared to its average volume of 1,149,361. Omada Health has a 12-month low of $14.14 and a 12-month high of $28.40.

About Omada Health

Omada's mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms.